AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for N6-adenosine-methyltransferase catalytic subunit

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q86U44

UPID:

MTA70_HUMAN

Alternative names:

Methyltransferase-like protein 3; N6-adenosine-methyltransferase 70 kDa subunit

Alternative UPACC:

Q86U44; O14736; Q86V05; Q9HB32

Background:

The METTL3-METTL14 heterodimer, acting as a N6-methyltransferase complex, plays a pivotal role in methylating adenosine residues in RNA. This modification influences various biological processes, including stem cell differentiation, neurogenesis, and the circadian clock. METTL3, as part of this complex, serves as the catalytic core, emphasizing its critical function in these pathways.

Therapeutic significance:

Understanding the role of N6-adenosine-methyltransferase catalytic subunit could open doors to potential therapeutic strategies. Its involvement in fundamental cellular processes and response to DNA damage highlights its potential as a target in regenerative medicine and cancer therapy.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.